Sort
50,496 grants matching “lung cancer”
Mechanisms of arsenic-induced chromosomal instability and carcinogenesis
$396,901Wei Dai · New York University School Of Medicine · R01 · FY2014 · ES
The Role of ADAM15 in Prostate Tumor Intravazation and Metastasis
$396,866Mark L Day · University Of Michigan At Ann Arbor · R01 · FY2011 · CA
Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor
$396,856Bruce R Zetter · Boston Children'S Hospital · R01 · FY2019 · CA
Fast dienophile reactions for in vivo click imaging
$396,840Ralph Weissleder · Massachusetts General Hospital · R01 · FY2010 · EB
S-Adenosylmethionine and Pneumocystis Treatment
$396,825Salim Merali · Temple Univ Of The Commonwealth · R56 · FY2010 · AI
Cancer Recurrence: Detection in Administrative Data, Incidence, and Costs
$396,816Michael James Hassett · Dana-Farber Cancer Inst · R01 · FY2013 · CA
Defining the impact of mutant oncogene zygosity
$396,790Sarat Chandarlapaty · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Predicting sensitivity and resistance in RET-driven cancers
$396,790Alexander Drilon · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
APOBEC proteins as drivers of chromosomal translocations in solid cancers
$396,790Roberto Chiarle · Boston Children'S Hospital · R01 · FY2022 · CA
Drivers of histologic transformation in EGFR-mutant lung cancer
$396,790Helena Yu · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Predicting sensitivity and resistance in RET-driven cancers
$396,790Alexander Drilon · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Defining the impact of mutant oncogene zygosity
$396,790Sarat Chandarlapaty · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Drivers of histologic transformation in EGFR-mutant lung cancer
$396,790Helena Yu · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Tissue and Airway Evaluation for Emphysema Intervention
$396,782Juerg Tschirren · Vida Technologies · R44 · FY2007 · HL
Research Project
$396,742Christi A Patten · Mayo Clinic Rochester · U54 · FY2014 · CA
Unmet needs for specific subsets of EGFR mutated lung cancer
$396,735Daniel Botelho Costa · Beth Israel Deaconess Medical Center · R37 · FY2019 · CA
Cause and Effect Relationships Between Glycation and the Ancestry Specific Tumor Stroma
$396,725David Paul Turner · Virginia Commonwealth University · R01 · FY2024 · CA
Regulation of KRAS plasma membrane targeting by defined glycosphingolipids.
$396,725John F Hancock · University Of Texas Hlth Sci Ctr Houston · R01 · FY2024 · GM
Tissue-Engineered Models of Lymphatic Drainage in Breast Cancer
$396,679Esak Lee · Cornell University · R01 · FY2025 · CA
Unmet needs for specific subsets of EGFR mutated lung cancer
$396,679Daniel Botelho Costa · Beth Israel Deaconess Medical Center · R37 · FY2023 · CA
Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE)
$396,664Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
RNA oxidation in RAS-driven cancer
$396,654Dimitri G Pestov · Rowan University School/Osteopathic Med · R21 · FY2024 · CA
Respiratory Diseases and Exposure to Elongated Mineral Particles in Taconite Ore
$396,651Gurumurthy Ramachandran · University Of Minnesota · R01 · FY2014 · OH
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
$396,625Aaron N Hata · Massachusetts General Hospital · R01 · FY2024 · CA
Erythropoietin Blockade for the Treatment of Cancer
$396,619C. Anthony Blau · University Of Washington · R01 · FY2008 · CA